Osiris Announces Implementation of Prestige Lyotechnology℠ Preservation Method Allowing Ambient Storage of Living Tissues
04 juin 2018 16h30 HE
|
Osiris Therapeutics, Inc.
COLUMBIA, Md., June 04, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (OTC Pink:OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics,...
Osiris Announces New Peer-Reviewed Publication Summarizing Clinical Outcomes of Viable Cryopreserved Placental Membranes for Management of Chronic Diabetic Foot Ulcers in Real World Setting
25 avr. 2018 16h30 HE
|
Osiris Therapeutics, Inc.
COLUMBIA, Md., April 25, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (OTC Pink:OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics,...
Osiris Therapeutics to Present Clinical and Scientific Studies at Symposium on Advanced Wound Care and Wound Healing Society Spring Conference
24 avr. 2018 16h30 HE
|
Osiris Therapeutics, Inc.
COLUMBIA, Maryland, April 24, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (OTC Pink Sheets:OSIR), a leading regenerative medicine company focused on developing and marketing products for...
Osiris Appoints Willi Miesch to its Board of Directors, Change in CEO
06 févr. 2018 16h30 HE
|
Osiris Therapeutics, Inc.
COLUMBIA, Md., Feb. 06, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (Pink Sheets:OSIR) is pleased to announce that its Board of Directors, at a Board Meeting on February 6th, 2018, appointed...
Osiris Therapeutics, Inc. Announces Resolution of SEC Investigation
02 nov. 2017 18h45 HE
|
Osiris Therapeutics, Inc.
COLUMBIA, Md., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (OTC Pink:OSIR) (the “Company”), a leading regenerative medicine company focused on developing and marketing products for...
Osiris Therapeutics, Inc. Provides Update on Audit of 2015 and 2016 Financial Statements
30 oct. 2017 16h30 HE
|
Osiris Therapeutics, Inc.
COLUMBIA, Md., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (OTC Pink:OSIR) (the “Company”), a leading regenerative medicine company focused on developing and marketing products for...
Osiris Announces a Peer-Reviewed Publication of a Scientific Study Reporting Antimicrobial Properties of Human Cryopreserved Viable Amniotic Membrane
23 oct. 2017 16h30 HE
|
Osiris Therapeutics, Inc.
COLUMBIA, Md., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (Pink Sheets:OSIR), a leading regenerative medicine company focused on developing and marketing products for wound care,...
Osiris Therapeutics to Present 10 Advanced Clinical and Scientific Abstracts, Including an Exclusive Oral Presentation on its New Ambient Viable Tissue Preservation Technology
19 oct. 2017 16h30 HE
|
Osiris Therapeutics, Inc.
COLUMBIA, Md., Oct. 19, 2017 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (Pink Sheets:OSIR), a leading regenerative medicine company focused on developing and marketing products for wound care,...
Osiris Announces a Peer-Reviewed Publication Reporting the Use of Placental Membranes for Refractory Cutaneous Sinus Tracts of Surgical Origin
05 oct. 2017 16h30 HE
|
Osiris Therapeutics, Inc.
COLUMBIA, Md., Oct. 05, 2017 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (Pink Sheets:OSIR), a leading regenerative medicine company focused on developing and marketing products for wound care,...
Osiris Appoints Linda Palczuk to serve as its President & CEO
26 juin 2017 09h15 HE
|
Osiris Therapeutics, Inc.
COLUMBIA, Md., June 26, 2017 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (Pink Sheets:OSIR) is pleased to announce that its Board of Directors has appointed Ms. Linda Palczuk, age 55, to serve as...